Department of Internal Medicine, Program in Molecular Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd. K3.124, Dallas, TX 75390, USA
Auto-generated profile, based on publicly available information
Maria Goralski
Department of Internal Medicine, Program in Molecular Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd. K3.124, Dallas, TX 75390, USA
An old cancer drug's degrading new look: Typically, cancer drugs that help only a small number of patients in clinical trials are not pursued. This might change in a future world of precision medicine, where biomarkers will match specific drugs to the patients most likely to respond. Han et al. identified the mechanism of action of a cancer drug called indisulam, a sulfonamide tested previously in patients with solid tumors. Indisulam and related sulfonamides killed cells by disrupting precursor mRNA splicing. The drugs targeted a specific RNA splicing factor for degradation by “gluing” it to the CUL4-DCAF15 ubiquitin ligase. Experiments with cancer cell lines suggest that future clinical trials of these drugs should focus on leukemias and lymphomas with high DCAF15 expression levels. Science , this issue p. eaal3755